Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Patients with Non-Small Cell Lung Cancer-Cachexia

Next Previous
X
Search
Trial Profile

A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Patients with Non-Small Cell Lung Cancer-Cachexia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Cachexia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 22 Jan 2021 According to an ONO Pharmaceutical media release, based on the results of ONO-7643-04 and ONO-7643-05 studies, the company has received the manufacturing and marketing approval of Adlumiz (anamorelin hydrochloride) Tablet 50mg (Adlumiz), for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.
    • 27 Nov 2018 According to an ONO Pharmaceuticals media release, base don the results of ONO-7643-04 and ONO-7643-05 study, company has submitted application for manufacturing and marketing approval of anamorelin hydrochloride (ONO-7643) for improvement of body weight loss and anorexia in patients with cancer cachexia in Japan.
    • 04 Dec 2017 Results published in the Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top